Stockreport

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

Tiziana Life Sciences Ltd - Common Shares  (TLSA) 
PDF Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi’s tolebrutinib for nrSPMS shows need [Read more]